{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:41:20Z","timestamp":1740120080788,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s12185-020-02948-0","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T17:03:03Z","timestamp":1595610183000},"page":"860-863","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Successful management of hemodialysis-dependent refractory myeloma with modified daratumumab, bortezomib and dexamethasone regimen"],"prefix":"10.1007","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2050-9907","authenticated-orcid":false,"given":"Shinichi","family":"Mizuno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chigusa","family":"Kitayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Sanada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshinobu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"2948_CR1","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","volume":"34","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kasritis E, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34:1544\u201357.","journal-title":"J Clin Oncol"},{"key":"2948_CR2","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","volume":"28","author":"MA Dimopoulus","year":"2010","unstructured":"Dimopoulus MA, Terpos E, Chana-Khan A, Leung N, Ludwig H, Jagannath S, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. J Clin Oncol. 2010;28:4976\u201384.","journal-title":"J Clin Oncol"},{"key":"2948_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/annonc\/mdt483","volume":"25","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis C, Repousis P, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25:195\u2013200.","journal-title":"Ann Oncol"},{"key":"2948_CR4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1182\/bloodadvances.2016003905","volume":"1","author":"C Botta","year":"2017","unstructured":"Botta C, Cilibetrto D, Rossi M, Staropoli N, Cuc\u00e8 M, Galeano T, et al. Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed\/refractory patients. Blood Adv. 2017;1:455\u201366.","journal-title":"Blood Adv"},{"key":"2948_CR5","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chana-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754\u201366.","journal-title":"N Engl J Med"},{"key":"2948_CR6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378:518\u201328.","journal-title":"N Engl J Med"},{"key":"2948_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16286","author":"MJ Cejalvo","year":"2019","unstructured":"Cejalvo MJ, Legarda M, Abella E, Cabezudo E, Encinas C, Garc\u00eda-Feria A, et al. Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study. Br J Haematol. 2019. https:\/\/doi.org\/10.1111\/bjh.16286.","journal-title":"Br J Haematol"},{"key":"2948_CR8","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1016\/j.clml.2020.03.014","volume":"20","author":"DC Moore","year":"2020","unstructured":"Moore DC, Arnall JR, Janes A, Pineda-Roman M. Dialysis independence following combination daratumumab, thalidomide, bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma with severe renal failure. Clin Lymphoma Myeloma Leuk. 2020;20:e395\u2013e398398.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2948_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.5045\/br.2020.55.1.65","volume":"55","author":"P Jeyaraman","year":"2020","unstructured":"Jeyaraman P, Bhasin A, Dayal N, Pathak S, Naithani R. Daratumumab in dialysis-dependent multiple myeloma. Blood Res. 2020;55:62\u20137.","journal-title":"Blood Res"},{"key":"2948_CR10","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s11845-018-1951-6","volume":"188","author":"E Smyth","year":"2019","unstructured":"Smyth E, Glavey S, Melotti D, Thornton P, Sargent J, Conlon P, et al. Dialysis independence following single-agent daratumumab in refractory myeloma with renal failure. Ir J Med Sci. 2019;188:1079\u201380.","journal-title":"Ir J Med Sci"},{"key":"2948_CR11","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.3324\/haematol.2018.191122","volume":"103","author":"S Rocchi","year":"2018","unstructured":"Rocchi S, Tacchetti P, Pantani L, Mancuso K, Zannetti B, Cavo M, et al. Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma. Haematologica. 2018;103:e277\u2013e278278.","journal-title":"Haematologica"},{"key":"2948_CR12","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","volume":"158","author":"J Blad\u00e9","year":"1998","unstructured":"Blad\u00e9 J, Fern\u00e1ndez-Llama P, Bosch F, Montol\u00edu J, Lens XM, Montoto S, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889\u2013933.","journal-title":"Arch Intern Med"},{"key":"2948_CR13","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","volume":"7","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a muliticentre, open-label, non-inferiority, randomized, phase 3 trial. Lancet Haematol. 2020;7:e370\u2013380.","journal-title":"Lancet Haematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02948-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-020-02948-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02948-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:12:59Z","timestamp":1627085579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-020-02948-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2948"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-02948-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2020,7,24]]},"assertion":[{"value":"1 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest associated with this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}